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1INTRODUCTION
Chronic kidney disease (CKD) encompasses a spectrum of
different pathophysiologic processes associated with abnormal renal function, and a
progressive decline in glomerular filtration rate (GFR). Pleural effusion in such patients is
a common diagnostic dilemma as it may arise from CKD itself (fluid overload, nephrotic
syndrome, uremic
pleurisy), concomitant infections (especially, tuberculosis (TB) in our country),
pulmonary embolisms or diseases causing pleuro-renal syndromes, like systemic lupus
erythematosus.
In tuberculosis (TB)-endemic countries, patients with exudative pleural effusion and
prolonged low grade fever in the absence of any other localization are “presumed” to be
of tubercular origin in “clinical perception” and empirically administered
antituberculosistherapy.Management of TB raises issues of drug dosing and interactions,
especially in renal transplant recipients.
Uremic pleurisy results from an unknown putative agent, and therefore uremic pleuritis is
a diagnosis of exclusion, that persists or recurs despite aggressive haemodialysis.
The presence of unilateral effusion suggests a diagnosis other than heart failure, like
tuberculosis or parapneumonic or atelectasis. The reduced humoral and cellular
immunity, in addition to delay in diagnosis because of an attenuated clinical response,
may explain the high rate of empyema.
2AIM OF THE STUDY
To study the etiology of pleural effusion in chronic kidney disease patients
in a tertiary care hospital
3REVIEW OF LITERATURE
NORMAL ANATOMY AND PHYSIOLOGY OF KIDNEY
The main function of the kidney is to maintain internal homeostasis  and giving
suitable environment for cellular metabolism and cellular  function. Kidneys achieve
these by excreting metabolic waste products, balancing solute and water transport,
conserving nutrients and also by maintaining acid-base balance. Kidneys also functioning
as a endocrine
organ by secreting renin, erythropoietin and 1,25-dihydroxy cholecalciferol (vitamin D)
which regulates blood pressure and electrolyte balance, RBC production and calcium
metabolism and bone mineral density respectively2.
ANATOMY
Kidneys are two paired organs situated in the retroperitoneal space  along the sides of the
vertebral column. They are extending between T12 vertebra to L3 vertebra. Because of
liver right kidney situated slightly lower than the left kidney. Each kidney is weighing
approximately 125 to 175 grams in male and 115 to 155 grams in female. Length of the
kidney is 11 to 12 centimeters, width is 5 to 7 centimeters and thickness is approximately
3 centimeters2. Renal artery, renal vein, ureters lymphatics and nerve plexus enters
kidneys via the renal hilum which is situated along  the medial surface of the kidney.
There is a renal capsule which surrounds the kidney.
After entering into hilum renal artery divides into anterior and posterior branches.
Anterior branch divides into three lobar or segmental arteries and supplies the anterior
surface of the kidney. The posterior branch of the renal artery supplies the posterior
4surface of the kidney and very rarely it gives an apical branch. These are end arteries;
there are no anastomoses between these arteries.
Kidney consists of outer cortex and inner medulla. There are 8 to 18 renal pyramids in
each kidney which are located in the medulla. The apices of the renal pyramid are
towards the renal pelvis and forms papilla; bases of the pyramids are towards the cortex.
Collecting duct opens into papilla.
Cortex contains all the glomeruli and portions of the tubules. The renal cortex is 1 cm
thick and extends between the pyramids to form the renal columns of Bertini. From the
base of the renal pyramid, at the corticomedullary junction, longitudinal elements termed
the "medullary   rays” extend into the cortex. These medullary rays are formed by
collecting ducts, proximal and distal tubules2.
Renal pelvis represents upper dilated end of ureter which is lined by transitional
epithelium. Two or three major calyces extend from the renal  pelvis, from which several
minor calyces extends towards the renal papilla and drain the urine. Lower part of renal
pelvis continued as
Renal pelvis represents upper dilated end of ureter which is lined by transitional
epithelium. Two or three major calyces extend from the renal  pelvis, from which several
minor calyces extends towards the renal papilla and drain the urine. Lower part of renal
pelvis continued as ureter and opens into the bladder. The renal pelvis represents the
upper urinary tract and is lined by transitional epithelium.  The major calyces which is
two or three in number, extends from renal pelvis. From major calyces, several minor
calyces extend toward the papillae and drain the urine. The ureters are 28 to 34 cm in
length, arise from lower part of the renal pelvis and open into the bladder. The smooth
5muscle is present in the walls of ureters produces peristaltic movement. With this
movement, urine from the kidney drains into the bladder.
THE NEPHRON
The nephron is the functional unit of the kidney, each kidney
consist approximately 1.2 million nephrons. The parts of the nephron are the glomerulus,
proximal tubule, loop of Henle, distal tubule, and the collecting duct. The nephron
develops from metanephricblastema. Embryologically collecting ducts develops from the
ureteric bud.  Nephrons are divided into two groups based on length of loop of henle. The
loop of Henle consists of thin descending limb and thick ascending limb. Cortical
nephrons have short loop of henle and juxta medullary nephrons have long loops.
GLOMERULUS
Glomerulus consists of tuft of capillaries lined by endothelial cells,
mesangial cells with mesangial matrix, the visceral and parietal layer of Bowman’s
capsule with basement membrane. Bowman's   space is situated between the visceral and
parietal epithelial layers. The diameter of the glomerulus is around 200 µm3. The
glomerulus produces the ultra-filtrate of plasma. The filtering unit consists of
endothelium, basement membrane, and the foot processes of the visceral epithelial cells.
Capillaries in the glomerulus is lined by fenestrated endothelial cells, these fenestrations
are surrounded by intermediate filaments and microtubules. This glomerulus endothelium
has negative charge; this is provided by Podocalyxin. Nitric oxide (vasodilator) and
endothelin-1 are synthesized by glomerular endothelial cells. VEGF receptors are seen in
the endothelial cells3. VEGF is produced by visceral epithelial cells and it increases
permeability of endothelial cells by increasing the formation of endothelial fenestrations
6and also VEGF is essential for survival and repair of endothelial cell in glomerular
diseases. Each epithelial layer in the glomerulus has unique structural properties that
allow components of the blood to pass through with the exception of blood cells and
plasma proteins of molecular weight greater than 70,000. The endothelial cells are the 8
barrier to prevent the passage of blood components from reaching Bowman's space.
Fig-1 Normal glomerulus
VISCERAL EPITHELIAL CELLS
The distance between two visceral epithelial cell foot processes is 25 to 60 nm. This is
filtration slit and is covered by a thin membrane called filtration slit membrane. A central
7filament is seen in the filtration slit diaphragm. Nephrin is the main constituent of the
filtration barrier. NPHS1 gene located in the chromosome 19 codes this nephrin;
Mutation of NPHS1 is noticed in congenital nephrotic syndrome of the Finnish type5.
Nephrin is seen in the visceral epithelial cells particularly in the slit diaphragm.
Deletion of CD2AP, which binds the nephrin to the cytoskeleton, is responsible for
congenital nephrotic syndrome. Mutation of the Podocin; a membrane protein that is seen
in filtration barrier is responsible for familial steroid-resistant nephrotic syndrome5. The
foot processes are replaced by cytoplasmic band which is termed as effacement of foot
process. Podoplanin maintains shape of foot process. The visceral epithelial cells are
responsible for the production and maintenance of the filtration membrane.
PARIETAL EPITHELIAL CELLS
Parietal epithelial cells are squamous epithelial cells. Recent evidences suggest that they
are progenitors of podocytes. After injury to podocytes these parietal epithelial cells
regenerates and forms podocytes. They also implicated in some form of proliferative
form of glomerulonephritis.
MESANGIAL CELLS
Irregularly shaped mesangial cells and its matrix constitute the
mesangium. Mesangial cells have dense nucleus and elongated cytoplasmic processes.
These processes consist of microfilaments such as actin, actinin and myosin. These cells
bridge the gap between glomerulus and basement membrane and prevent distension of
capillaries. Mesangial matrix composed of glycosaminoglycans and collagen4. Mesangial
cells are  specialized form of pericyte; having many characteristics of smooth muscle
8cells. They are providing support to glomerular capillaries, regulates glomerular filtration
rate and synthesizes Mesangial matrix4.
GLOMERULAR BASEMENT MEMBRANE
The glomerular basement membrane consists of two thin layers the
lamina raraexterna and the lamina rarainterna and a dense layer the lamina densa.
Basement membrane composed of type IV collagen. Mutation of the α3, α4, and α5
chains causes Alport’s syndrome. Podocalyxin present in the glomerular basement
membrane gives its negative charge. Presence of anionic site in the basement membrane
is demonstrated by Caulfield and Farquhar with the use of lysozyme. These anionic sites
in the basement membrane are made up of glycosaminoglycans such as heparan sulfate4.
JUXTAGLOMERULAR APPARATUS
Juxtaglomerular apparatus is situated where the afferent and
efferent arterioles meet the distal convoluted tubule. It is named because of its proximity
to the glomerulus. JG apparatus controls function of each kidney. Components of the
juxtaglomerular apparatus are macula densa, juxtaglomerular cells and extra glomerular
mesangium. Macula densa is formed by cells of the distal convoluted tubule. Macula
densa senses the sodium chloride concentration in the tubular fluid and secretes the
locally  acting vasoactive substance, there by controls the GFR by changing efferent
arteriole diameter as a part of tubuloglomerular feedback4.
9JUXTAGLOMERULAR GRANULAR CELLS
Juxtaglomerular granular cells are present in the walls of the
arteriole and extra glomerular mesangial region. They are having characteristics of both
smooth muscle cells and epithelial cells. These cells contain renin and its precursor
granules.
EXTRA GLOMERULAR MESANGIAL CELLS
Also known as lacis cells or the cells of goormaghtigh situated
between the afferent arteriole and macula densa. Functions of the cells are not clearly
known. It may be associated with secretion of erythropoietin.
PROXIMAL TUBULE
Proximal tubule is a portion of the nephron which extends from the
Bowman’s capsule and extends up to loop of henle. It consists of proximal convoluted
portion knows as pars convoluta and distal straight portion known as pars recta. Pars
convoluta entirely situated in the cortex. It maintains the PH of the filtrate absorbs the
most of the filtered components and secretes the creatinine and organic acids6.
Approximately two-third of  the filtered water, 100% of the glucose and amino acids are
absorbed from the proximal convoluted tubule.
LOOP OF HENLE
It is a U shaped portion of nephron situated in between the
proximal and distal convoluted tubule. Most important function of the loop of henle is to
provide high osmotic gradient inside the medulla by counter current system. With the
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help of ion channels it creates high concentration in the medulla, so water is absorbed
from the filtrate according to osmotic gradient.
DISTAL CONVOLUTED TUBULE
It is situated between the ascending limb of loop of Henle and
collecting duct of the renal tubule. It maintains the PH, regulates electrolyte balance.
Vasopressin acts through the receptors situated in the collecting duct and facilitates water
reabsorption. Na+/cl- channels present in the distal convoluted tubules are thiazide
sensitive. By inhibiting these channels, thiazide causes luminal Na+ gradient and also
diuresis6.
FUNCTIONS OF THE KIDNEY
A. Maintain water homeostasis.
B. By producing erythropoietin, active form of vitamin D and renin acts      as a endocrine
organ
C. Regulation of acid base balance.
D. Elimination of metabolic waste products.
E. Excretion of toxic substances from the body.
F. Blood pressure maintenance
G. Catabolism of small peptide hormones
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CHRONIC KIDNEY DISEASE
Chronic kidney disease is emerging as a major health related issue
worldwide. Developing countries like India are not able to manage these patients because
of increasing cost. Incidence and prevalence of CKD is increasing because of the
increased survival and improved quality of treatment. The term chronic renal failure
corresponds to CKD stages 3-5, applies to the processes of irreversible reduction in
nephron number. End stage renal disease represents the stage in which survival is not
possible, unless the uremic toxins are removed by appropriate renal replacement therapy.
This syndrome is caused by accumulation of toxins, fluids and electrolytes that are
normally excreted by kidneys.
Most common causes of ESRD are diabetes, hypertension,
polycystic kidney disease and glomerulonephritis. These together contribute to more than
90% of the cases of ESRD. Other causes for CKD include interstitial nephritis and
HIV119. Nephropathy due to systemic hypertension is the most common cause for end
stage renal disease in elderly patients. Nephrosclerosis from vascular disease process
correlates with coronary and cerebrovascular disease. Because of decreased mortality
related to atherosclerotic coronary complications, greater segment of the population
manifests the renal counter part of generalized vascular disease. In early stages of CKD,
34  patients usually will die of cardiovascular and cerebrovascular complications before
they progress to ESRD. Renal disease progression varies from person to person, so this
leads to genetic research to identify the inheritable component. A number of genetic loci
that are contributing to the development of kidney disease have been identified.
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Chronic kidney disease is divided into five stages based on the estimated glomerular
filtration rate (GFR). In stage 1and stage 2 the GFR is normal or near normal, so based on
the structural or functional defect these two are differentiated.
DEFINITION OF CHRONIC KIDNEY DISEASE
The National Kidney Foundation [Kidney Disease Outcomes
Quality Initiative (KDOQI)] has proposed a definition and classification scheme of CKD.
The National kidney foundation guidelines define CKD on the basis of kidney damage
and/or reduced renal function. Kidney damage may be confirmed through a variety of
methods including renal imaging, abnormalities in the serum or urine biochemistry and
histological evidence. Albuminuria is the most frequent early indicator of kidney damage.
CRITERIA:
1. Structural or functional abnormality of the kidney for more than 3 months, with or
without decreased urine output, manifested by
 Pathological abnormalities
 Markers of kidney damage
 Urinary abnormalities (proteinuria).
 Blood biochemical abnormalities.
 Imaging abnormalities.
2. GFR<60 ml/min/1.73m2 BSA for >3 months with or without
kidney damage.
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RISK FACTORS FOR CKD
Established risk factors:
 Age
 Gender
 Race
 Diabetes mellitus
 High blood pressure
 Proteinuria
 Atherosclerosis
 Family history of kidney disease
 Reduced nephron number at birth
 Obesity
 Metabolic syndrome
 Family history of kidney disease
 Smoking
 Exposure to nephrotoxins
 Dyslipidaemia
 Recurrent urinary tract infection
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Emerging risk factors:
 Elevated plasma homocysteine level
 Oxidative stress
Prothrombotic factors (e.g. Plasminogen activator protein)
 Anaemia
STAGES OF CHRONIC KIDNEY DISEASE
Kidney disease outcome quality initiative (NKF-KDOQI) staging
system: Importances of this staging are
1. It shifts the focus from GFR as the sole criteria for defining chronic
kidney disease to the identification of markers of early kidney
damage including proteinuria and abnormal urinary sediment.
2. The concept of CKD with normal glomerular filtration rate, but with markers of kidney
damage like persistent proteinuria is providing guidelines for optimal treatment at early
stage.
This system of staging helps us to plan for further treatment and also helps in predicting
the outcomes. Thus there is a need for early detection
and treatment.
CAUSES OF CHRONIC KIDNEY DISEASE
1. Diabetic glomerulosclerosis 2. Hypertensive Nephrosclerosis.
3. Glomerular diseases:
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 Glomerulonephritis
Amyloidosis, light chain disease.
Systemic lupus erythematosus.
Wegener’s granulomatosis.
4. Tubulointerstitial diseases:
 Reflux nephropathy (chronic pyelonephritis).
Analgesic nephropathy.
 Obstructive nephropathy (stones, benign prostatic
hypertrophy).
Myeloma kidney.
5. Vascular diseases:
Scleroderma.
Vasculitis.
 Reno vascular renal failure
Atheroembolic renal disease.
6. Cystic diseases:
ADPKD.Medullary cystic kidney disease.
There is a difference between the etiologies of CKD in India when
compared to world-wide incidence. For example, in North America the
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commonest cause for CKD is diabetic nephropathy and the next being hypertensive
glomerulosclerosis. But in India although large scale data are unavailable,
glomerulonephritis is the leading cause for CKD over diabetes and hypertension.
In most of the patients while diagnosing CKD, there is an associated systemic
hypertension. If there is no identifiable cause for glomerular disease or tubular pathology,
the etiology is often attributed to systemic hypertension. But such patients without
identifiable etiological factors are considered in the following categories.
1) Patient with silent primary glomerulopathy, like focal segmental glomerulosclerosis
without overt nephrotic or nephritic manifestations of glomerular disease.
2) Patients with chronic renal ischemia attributed to systemic vascular disease involving
large and small vessels, cardiac and cerebral pathology. Here systemic hypertension is
considered to be the renal correlate of systemic vascular disease.
PATHOPHYSIOLOGY OF CKD
It involves two broad sets of mechanisms
1. According to the mechanisms that are specific to the underlying etiology
that initiate the kidney damage. (e.g. Genetic abnormalities in the development of kidney,
deposition of immune complexes and inflammatory mediators as in glomerulonephritis or
exposure of toxins in diseases of renal tubules and interstitium).
2. Progressive mechanisms involving hyper filtration and hypertrophy of the remaining
viable nephrons that are common consequence following reduction of renal mass,
irrespective of the underlying etiology. These adaptive responses to reduction in nephron
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number are mediated by a number of vasoactive hormones, cytokines and growth factors.
Renin aldosterone system is responsible for hyperfiltration and subsequent
hypertrophy and sclerosis. The increased intra-renal renin activity contributes to both
initial inciting event and also to the progressive mechanisms, finally leading on to
the glomerular sclerosis, renal failure and uremic syndrome.
PATHOPHYSIOLOGY OF UREMIC SYNDROME
The pathophysiology behind the uremic syndrome can be classified
into 1) Due to the accumulation of toxins that are normally excreted via the kidneys.
2) Due to impairment of fluid and electrolyte homeostasis and hormone regulation.
3) Progressive systemic inflammation and its consequences Various excretory products
accumulating in renal dysfunction are nitrogenous and non-nitrogenous products such as
urates, products of nucleic acid metabolism, phenols, guanido compounds, hippurates,
indoles, middle molecules, etc. Accumulation of these waste products leads to
anemia, metabolic abnormalities of carbohydrate, protein and fat and malnutrition
resulting in a clinical syndrome which is characteristic feature of end stage renal disease.
There is alteration of metabolism of many hormones like insulin, glucagon, PTH and
vitamin-D due to increased renal excretion, decreased degradation and abnormal
regulation.
FACTORS INFLUENCING RENAL PROGRESSION
There are some factors affecting the progression of renal disease.
The rate of disease progression can be modified by modifying these riskfactors. It
includes:
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1. Hypertension.
2. Diabetes.
3. Hyperlipidaemia.
4. Abnormal calcium-phosphorus homoeostasis.
5. Genetic factors.
6. Cigarette smoking.
7. Renin-angiotensin system activation.
8. Excessive dietary protein.
9. Obesity.
10.  Prematurity/low birth weight.
CLINICAL PRESENATION
Most of the patients are asymptomatic in the early stages of chronic
kidney disease; mostly they do not come to medical attention until most of the kidney
function is compromised by the disease process. Any organ system can be affected by the
kidney disease. Anemia, proteinuria and hypertension are the most common
manifestations present in the most of the patients. Clinical presentation depends upon the
systems involved.
These include:
1) Disorders of fluid, electrolyte and acid-base homeostasis
2) Disorders of calcium and phosphate metabolism
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3) Disorders of cardiovascular system
4) Haematological abnormalities
5) Neuro-muscular abnormalities
6) Gastro-intestinal and nutritional abnormalities
7) Endocrine-metabolic disturbances
8) Dermatological abnormalities
ELECTROLYTE AND ACID-BASE DISORDERS
SODIUM AND WATER HOMEOSTASIS
In patients with stable CKD, there is a clinically insignificant increase in total body water
and sodium content. In most of the CKD patients daily intake of sodium exceeds its
urinary excretion leading to sodium retention and extracellular volume expansion. This is
also one of the contributing factors for development of hypertension. Hyponatremiais
very rarely seen in CKD patients; even if present it will respond to water restriction.
Definition
Pleural effusion is defined as the abnormal accumulation of pleural fluid within the
pleural cavity. Crucial feature of the breathing apparatus is the pleural space. This is a
potential space between the parietal pleura and the visceral pleura It is the coupling
system between the lung and the chest wall .
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ANATOMY OF PLEURA
The lung parenchyma, the diaphragm , the mediastinum and the rib cage are
covered by a serous membrane called the pleura. Pleura is divided into visceral pleura
and parietal pleura. At the lung root , the visceral and parietal pleura meet.
Visceral pleura :
It covers the lung parenchyma in its points of contact with the diaphragm ,the
mediastinum and the chest wall and also in the interlobar fissures.
Parietal pleura :
It lines inside of the thoracic cavities.  It is subdivided on the basis of intrathoracic
structures that it lines in to
1. Costal parietal pleura ,
2. Mediastinal parietal pleura,
3. Diaphragmatic parietal pleura.
Pulmonary ligament :
This is a thin double fold of pleura formed due to the downward extension of the pleura ,
posterior to the lung root.
Pleural space :
This is a potential space between the the visceral pleura and parietal pleura.
Pleural fluid :
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This is a thin film of fluid  normally present in between the visceral pleura and parietal
pleura ie., pleural space
Functions of pleural fluid - acts as a lubricant . During the respiratory movements the
pleural fluid allows the visceral pleura which is covering the lung to slide along the
parietal pleura which is lining the thoracic cavity.
HISTOLOGY OF PLEURA :
Parietal pleura - composed of loose , irregular connective tissue which is covered by a
single layer of mesothelial cells. Within the pleura there are blood vessels , mainly
capillaries and lymphatic lacunas. Endothoracicfascia is situated  deeper to parietal
pleura. This is a continuous dense band of irregular connective tissue. This is mainly
composed of elastin and collagen and it covers ribs and intercostal spaces.
Visceral pleura – composed of two layers namely the mesothelium and the connective
tissue.
Connective tissue layer functions :
1. Contributes to elastic recoil of lung ,helps in expelling air from thelung
2. Restricts the volume of lung to which the lung can be inflated , and thereby protecting
the lung
Mesothelialcells  functions :
It forms a monolayer of pavement like cells lining the pleural surfaces.
1. Movement and transport of particulate matter and fluid across thepleuralsurfaces .
2. Migration of leucocytes in response to inflammation .
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3. Synthesis of cytokines , growth factors , EC matrix proteins .
4. Antigen presentation and transformation to myofibroblasts .
Blood supply :
Parietal pleura receives blood supply from systemic capillaries such
as intercostal artery ,pericardiophrenic artery , superior phrenic and musculophrenic
artery  and drained by intercostal veins , phrenic veins. Visceral pleura : Blood supply of
thin pleura is derived from pulmonary circulation , and that of thick pleura is derived
from bronchial arteries. Venous drainage is through the pulmonary veins.
Lymphatic drainage :
Lymphatic plexus in the parietal pleura drains in to intercostal
,mediastinal, tracheobronchial , parasternal and phrenic nodes. In the parietal pleura the
lymphatic vessels are in communication with the stomas, the diameter of which ranges
between 2 to 6 microns.  The main pathways for the elimination of particulate matter is
the stomas with lacuna and lymphaticsvessels . In the visceral pleura there are abundant
lymph vessels which joins bronchial lymph vessels.
Nerve supply :
Intercostal nerves supply the costal and peripheral part of
diaphragmatic pleura. So the pain sensation due to inflammation of this pleura is
perceived in the chest wall. Phrenic nerve supplies the central part of diaphragmatic
pleura . So when this part of pleura is irritated or inflamed the pain is felt in the
ipsilateralshoulder.
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PHYSIOLOGY OF PLEURA
Formation of the Pleural Fluid :
Pleural fluid can originate in the
pleural capillaries,
the intra-thoracic lymphatics,
theintrathoracic blood vessels,
the peritoneal cavity , or
the interstitial spaces of the lung,
Pleural Capillaries
Starling's law of transcapillary exchange governs the movement of fluid between the
pleural capillaries and the pleural space .
Hydrostatic pressure :
In the parietal pleura , the hydrostatic pressure is approximately 30 cm H2O,but  the
pleural pressure is approximately -5 cm H2O. The net hydrostatic pressure is therefore 30
- (-5) = 35 cm H2O .This pressure favorsthe movement of fluid from the capillaries in the
parietal pleura to the pleural space.
Oncotic pressure :
This hydrostatic pressure gradient is  opposed by oncotic pressure gradient. Plasma
oncotic pressure is approximately 34 cm H2O.  Normally, the pleural fluid has an oncotic
pressure of approximately 5 cm H2O, as it contains a small amount of protein .The  net
oncotic pressure gradient is 34 - 5 = 29 cm H2O. Thus, the net gradient is 35 - 29 = 6 cm
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H2O. It favours the movement of fluid to the pleural space from the capillaries in the
parietal pleura. The net gradient for fluid movement across the visceral pleura in humans
is probably close to zero, which has not been demonstrated. The
pressure in the parietal pleural capillaries is approximately 6 cm H2O more than that in
the visceral pleural capillaries.
This is  because the visceral pleural capillaries is drained by the pulmonary veins.  Also
this is the only pressure that differs from those  pressure affecting fluid movement across
the parietal pleura. The net gradient for the parietal pleura is 6 cm H2O. So the net
gradient is approximately zero for the  fluid movement across the visceral pleura.  The
capillaries in the visceral pleura when compared to those in the parietal pleura , are much
farther from the pleural space .So  the filtration coefficient (Lp) for the visceral pleura is
substantially less than that for the parietal pleura . When compared with the intercostal
spaces ,the fluid formation  is more across the parietal pleura over the ribs. Also fluid
formation was more over the caudal ribs than over the cranial ribs.  But in contrast,
pleural liquid absorption was more primarily in the parietal pleura adjacent to the
intercostal space rather than in the parietal pleura overlying the ribs. The formation of
pleural fluid was more, if the breathing frequency was ncreased.
Interstitial Origin
It has been demonstrated that the  interstitial spaces of the lungs, is the origin of much of
the fluid that enters the pleural space. Pleural fluid accumulates if there is either high-
pressure or high-permeability pulmonary edema.Theelevation in the wedge pressure is
directly related to the amount of pleural fluid formed. But only after the development of
pulmonary edema, increases in pleural fluid accumulation occur.
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In patients with congestive heart failure , the origin of the pleural effusion is probably the
pulmonary interstitial space. It is likely that many conditions associated with lung injury,
such as lung transplantation and pulmonary embolization , the origin of the pleural fluid
is also the interstitial spaces of the lung. It has been shown that the subpleural interstitial
pressure increases, with increasing levels of interstitial fluid. Even though the visceral
pleura is thin, the barrier to the movement of fluid across the visceral pleura appears to be
weak. Therefore, once there is increase in  subpleural interstitial pressure, the
fluid will enter to the pleural space through the visceral pleura.  Peritoneal Cavity
If there is free fluid in the peritoneal cavity,  pleural fluid accumulation can occur.
Peritoneal fluid enters the pleural space through the openings in the diaphragm. Since the
pressure in the pleural cavity is less than the pressure in the peritoneal cavity the fluid
will flow from the peritoneal space to the pleural space. In the following conditions like
hepatic hydrothorax, Meigs'  syndrome, and peritoneal dialysis, the peritoneal cavity is
the origin of the pleuralfluid.
Thoracic Duct or Blood Vessel Disruption
If there is disruption of thoracic duct, there is accumulation of lymph in the
pleuralspace.Thiswill  produce a chylothorax. With chylothorax the rate of fluid
accumulation can be more than 1,000 mL/day.
Origin of Normal Pleural Fluid
It is believed that the fluid that normally enters the pleural space originates in the
capillaries in the parietal pleura. The amount of pleural fluid formed daily is
approximately 15 mL in a 50-kg individual. Since  in the interstitial spaces the protein
level is normally approximately 4.5 g/dL, and the protein level in normal pleural fluid is
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only approximately 1 to 1.5 g/dL, the origin of the fluid does not appear to be the
interstitial spaces of the lung . Pleural fluid with lower protein levels are produced by
higher vascular pressures . Evans blue dyed albumin  studieswith rabbits have
demonstrated that most fluid originates in the parietal pleura over the ribs .
Pleural Fluid Absorption
Lymphatic Clearance
The lack of fluid accumulation in normal individuals is due to the clearance of fluid
through the pleural lymphatics. By means of stomas in the parietal pleura , the pleural
space is in communication with the lymphatic vessels in the parietal pleura. Visceral
pleura lacks such stomas. The lymphatics in the parietal pleura, removes proteins, cells,
and all other particulate matter from the pleural space. The carbon particles exit the
pleural space through the stomas ,where the mesothelial cells are small and not flattened .
These stoma  increases in diameter in response to increased levels of nitric oxide in the
pleural space. In a 60-kg individual the lymphatic drainage from each pleural space is on
the order of 20 mL/hr or 500 mL/day.  Once the volume of the pleural liquid exceeds a
certainthreshold, thelymphatics operate at maximum capacity. The capacity for lymphatic
clearance is 28 times as high as the normal rate of pleural fluid formation.
Clearance through Capillaries in Visceral Pleura
Until the mid-1980s, it was thought that the capillaries in the visceral pleura in humans is
the primary route for the exit of fluid from the pleural space.   Through the lymphatics in
the parietal pleura almost all the pleural fluid is removed. Several hundred milliliters of
water probably traverse the pleural membranes each day. Since the osmolarity is nearly
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identical on each side of the membrane , the net movement is of only a few milliliters.
Alternative Mechanisms for Pleural Fluid Removal
In  the removal of protein from the pleural space , transcytosis plays a role and there is
some evidence for that. Only 29% of the overall removal of albumin occurred through the
stoma with small hydrothoraces, while 64% of the albumin from large hydrothoracesas
removed through the stoma
Pathogenesis of Pleural Effusions
Whenever the rate of pleural fluid formation exceeds the rate of pleural fluid absorption,
there is accumulation of pleural fluid.  Normally, from the capillaries in the parietal
pleura, a small amount (0.01 mL/kg/hour) of fluid constantly enters the pleural space.
The lymphaticsin the parietal pleura removes  almost all of this fluid . Lymphatics have a
capacity to remove at least 0.20 mL/kg/hour. The lymphatics remove the fluid exceeding
the normal rate of fluid formation by a factor of 20.
DIFFERENTIAL DIAGNOSIS OF PLEURAL EFFUSION :
I. Transudative pleural effusions
 Congestive heart failure
 Cirrhosis
 Nephrotic syndrome
 Cerebrospinal fluid leaks to pleura
 Hypoalbuminemia
 Sarcoidosis
 Peritoneal dialysis
 Glomerulonephritis
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 Myxedema
 Superior vena caval obstruction
 Fontan procedure
 Urinothorax
II. Exudative pleural effusions
A. Neoplastic diseases
1. Metastatic disease
2. Mesothelioma
3. Pyothorax-associated lymphoma
4. Body cavity lymphoma
B. Infectious diseases
1. Bacterial infections
2. Tuberculosis
3. Viral infections
4. Parasitic infections
5. Fungal infections
C. Pulmonary embolization
D. Gastrointestinal disease
1. Pancreatic disease
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2. Subphrenic abscess
3. Intrahepatic abscess
4. Heart diseases Postcoronary artery bypass graft surgery
5. Postcardiac injury (Dressler's) syndrome
6. Pericardial disease
7. Diaphragmatic hernia
8. Endoscopic variceal sclerosis
9. Postliver transplant
10. Pulmonary vein stenosis postcatheter ablation of atrial fibrillation
11. Intrasplenic abscess
12. Esophageal perforation
13. Postabdominal surgery
E.Obstetric and gynecologic disease
1. Ovarian hyperstimulation syndrome
2. Fetal pleural effusion
3. Endometriosis
4. Postpartum pleural effusion
5. Meigs' syndrome
F.Collagen vascular diseases
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1. Rheumatoid pleuritis
2. Systemic lupus erythematosus
3. Familial Mediterranean fever
4. Churg-Strauss syndrome
5. Wegener's granulomatosis
6. Drug-induced lupus
7. Immunoblastic lymphadenopathy
8. Sjogren's syndrome
G.Drug-induced pleural disease
1. Ergot drugs
2. Amiodarone
3. Interleukin 2
4. Nitrofurantoin
5. Dantrolene
6. Methysergide
7. Procarbazine
8. Clozapine
9. Methotrexate
H.Miscellaneous diseases and conditions
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1. Sarcoidosis
2. Uremia
3. Trapped lung
4. Acute respiratory distress syndrome
5. Whipple's disease
6. Iatrogenic pleural effusions
7. Asbestos exposure
8. Postlung transplant
9. Postbone marrow transplant
10. Yellow nail syndrome
11. Electrical burns
12. Extramedullaryhematopoiesis
13. Rupture of mediastinal cyst
14. Therapeutic radiation exposure
15. Drowning
16. Amyloidosis
17. Milk of calcium pleural effusion
I.Hemothorax
J. Chylothorax
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GENERAL TESTS TO DIFFERENTIATE THE CAUSES OF
EXUDATIVE PLEURAL EFFUSION :
1.Appearance of the fluid :
Mostly transudative and many exudative pleural effusions are clear , straw colored ,
nonviscid and odourless. The red colour of the fluid indicates the presence of blood. To
confirm hemothorax we have to do a hematocrit. If the hematocrit of the pleural fluid was
more than 50 % of the peripheral blood hematocrit , then it is a hemothorax. When the
pleural fluid is blood tinged  the RBC count is 5000 to 10000 / mm3 . If the pleural fluid
macrophages contain haemoglobin inclusions , then it indicates that the blood was present
before thoracentesis and the blood is not due to traumatic tap. Increased lipid content or
increased cellular content both can make pleural fluid to appear turbid . If after centrifuge
the supernatant fluid remains turbid then it is due to lipid content. But if the supernatant
fluid is clear , then the turbidity is due to cellular debris .
Amebiasis with a  hepatopleural fistula – chocolate sauce or anchovy paste.
The mixture of blood ,cytolysed and normal liver tissue make this appearance.
Malignant mesothelioma – high viscocity due to elevated  hyaluronic acid .
Anaerobic bacterial infection – feculent odour
Urinothorax – smell of urine
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2.WBC count :
Most transudates have WBC count below 1,000/mm3 and exudates have more than
1,000/mm3.
WBC count > 10,000/mm3 – parapneumonic effusions
WBC count > 50,000/mm3 – pancreatic disease and pulmonary embolism
Neutrophils predominate – suggests acute inflammation . It is seen in pneumonia ,
pancreatitis , pulmonary embolisation ,subphrenic abscess , early tuberculosis .
Eosinophils predominate – indicates air or fluid in the pleural  space. It is seen in patients
with spontaneous pneumothorax who undergone thoracotomy , introduction of air during
thoracentesis into pleural space , traumatic hemothorax , pulmonary embolization ,
CABG , asbestos related effusion , drugs like dantrolene , bromocriptine , parasitic
disease like amebiasis , ascariasis .
Basophils  predominate – pneumothorax , pneumonia , leukemic pleural involvement .
Pleural fluid lymphocytosis - malignancy , TB , CABG , leukemia or lymphomas .
Mesothelial cells – Tuberculosis in HIV patients . Whereas it is absent in complicated
parapneumoniceffusions , malignancy after pleurodesis.
3.Glucose levels :
Glucose level < 60 mg / dL – malignancy ,parapneumoniceffusions,rheumatoid disease ,
tuberculosis . Other causes include hemothorax , lupus pleuritis ,paragonimiasis , churg –
strauss syndrome .
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4.Amylase level :
It is elevated in pancreatic disease , malignancy , esophageal rupture . In later two cases
the amylase is of salivary type.
5.Lactate dehydrogenase level :
LDH in the pleural fluid is a reliable indicator of degree of  inflammation of the pleura.
More the inflamed surfaces , higher the LDH levels . The most common causes of
elevated LDH levels are parapneumonic effusions and malignancy . These two conditions
mostly meet the light’s criteria on the basis of levels of LDH than the protein levels .The
isoenzymes elevated in these conditions are LDH – 4 and LDH – 5. They are thought to
arise from the inflammatory WBC .
Usually LDH isoenzyme is not used routinely . This is done in conditions where there is
a bloody pleural fluid tap in a patient who is having transudative pleural effusion
clinically .The pleural fluid protein meets the criteria for transudative pleural effusion but
LDH levels meets the criteria for exudative pleural effusion. In these conditions
isoenzyme LDH – 1 , confirms that the rise in LDH was due to blood .
6.Pleural fluid pH :
If the pleural fluid pH is less than 7.2 then we have to consider the following causes :
complicated parapneumonic effusions , esophageal rupture , rheumatoid pleuritis ,
tuberculouspleuritis malignant pleural disease , hemothorax , systemic acidosis , lupus
pleuritis , paragonimiasis , urinothorax .
7.AdenosineDeaminase :
ADA has two isoenzymes – ADA 1 and ADA 2
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ADA 1 is produced by lymphocytes , neutrophils , monocytes , macrophages
ADA 2 is produced by macrophages and monocytes .
The cut off level for ADA level to diagnose tuberculous pleural effusion is  40 to 45 U/L
. The diagnosis of TB pleural effusion is more likely if the level is higher ie., more than
70 U/L .
Other conditions with elevated ADA levels are empyema , rheumatoid pleuritis,
neoplasms , Q fever , brucellosis . If the ADA 1 to ADA  ratio is less than 0.42 the
diagnosis of TB pleuritis is increased .
8.Interferon gamma :
In patients with tuberculouspleuritis CD 4 lymphocytes  produce interferon gamma . It
enhances the elimination of  intracellular parasites by increasing the production of
polymyristate acetate induced hydrogen peroxide in macrophages. In monocytes this
inhibits the mycobacterial growth . If the interferon gamma level is more than 200 pg / ml
then the diagnosis of   tuberculouspleuritis is made.
9.Polymerase chain reaction :
It is used in patients with low  numbers of tubercle bacilli  in pleural fluid . It is also used
on pleural biopsy specimens .
10. C – Reactive proteins more than 50 mg /L , high levels of lysozyme are also used to
diagnose tuberculouspleuritis .
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10.Lipids :
Chylothorax – Accumulation of chyle in the pleural space due to distruption of the
thoracic duct. In these situations the triglyceride levels are increased .Chyliform pleural
effusions – This is characterised by high levels of lecithin globulin levels .
Pseudo chylous effusions – There is increased levels of cholesterols crystals .
Triglyceride levels more than 110 mg / dL – Chylothorax is confirmed . But if the levels
are less than 50 mg / dL then the patient is not having chylothorax .
If triglyceride level is between 50 to 110 mg / dL then we need to perform a lipoprotein
analysis. Chylothorax is diagnosed if there is presence of chylomicrons in the lipoprotein
analysis of  pleural fluid.
11.Bilirubin
Bilirubin has a high molecular weight (584) .With respect to its concentration between
serum and protein it behaves in a manner identical  to that of the high molecular weight
proteins . Any serous membrane inflammation often leads to increased capillary
permeability and this enables the diffusion of high molecular weight bilirubin .
A pleural fluid bilirubin of more than 0.48 mg / dL and a pleural fluid bilirubin to serum
bilirubin ratio of more than 0.62 is considered as exudates.
12.Cholesterol
The mechanism of  increased concentration of cholesterol in Exudative pleural effusion
is not known clearly. The permeability of pleura is increased due to “serum leakage” and
this leads to the accumulation of cholesterol in exudative pleural effusion .A pleural fluid
cholesterol of more than 60 mg / dL is used in diagnosing exudates.
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RADIOGRAPHIC EXAMINATIONS  OF PLEURAL EFFUSIONS
Typical Arrangement of Free Pleural Fluid
In the pleural space the distribution of free fluid is influenced by two main factors.
First, since the lung is less dense than pleural fluid, accumulation of the  pleural fluid
occurs in the most dependent part of the thoracic cavity.  The distribution of fluid within
the free pleural space obeys the law of gravity. The lung also maintains its shape when
compressed. Bearing, these 2 factors in mind  it is easy to predict the distribution of
excess pleural fluid.  The fluid first gravitates to the base of the hemithorax and comes to
rest between the inferior surface of the lung and the diaphragm, where the pleural sinus is
the most inferior, particularly posteriorly. The fluid spills out into the costophrenic
sinuses posteriorly, laterally, and anteriorly, when the fluid accumulation is higher.
Additional fluid assumes a higher position in the thorax as it  spreads upward in a mantle-
like manner around the convexity of the lung and gradually tapers .
The lateral costophrenic angle is obliterated, in the posteroanteriorprojection.The density
of the fluid is high laterally and curves gently medially and downward , to terminate at
the mediastinum with a smooth, meniscus-shaped upper border. At the mediastinal border
the layer of fluid is narrower than at the costal border.
The upper surface of the pleural fluid density is semicircular in the lateral projection. It is
high in the anterior and posterior regions. It curves smoothly downward to its lowest
point approximately midway between the posterior chest walland the sternum .
Frequently, in the lateral chest radiograph  a middle lobe step  is observed . The
explanation for the middle lobe step is that the most dependent and the the first affected
lobe is the lower lobe , the pleural fluid  starts to accumulates here. Therefore, it starts to
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float and shrink but maintains its shape. So the middle lobe is unaffected and its full
volume is maintained . Accordingly, the result is a a middle lobe that retains its usual size
and shrunken lower lobe . The fluid accumulation is mostly in the posterior part of the
chest ,radiographically. The height of the pleural fluid is greater laterally , based on the
radiologic appearance. When viewed en face ,this layer of fluid is of insufficient depth to
cast a discernible shadow, so it assumes a meniscus shape.
Radiologic Signs
The fluid first accumulates between the inferior surface of the lower lobe and the
diaphragm, when the patient is in the upright position. The pleural fluid  occupies this
position , if the amount of fluid is small (approximately 75 mL) and without spilling into
the costophrenic sinuses. The normal configuration of the diaphragm is maintained, with
this small amount of fluid.
The chest radiograph does not demonstrate that pleural fluid is present.  When viewed in
the lateral projection , accumulation of more fluid obliterates the costophrenic angle as it
spills over into the posterior costophrenic angle  . The posterior costophrenic angle is
normally sharp . It is obliterated by a homogeneous , shallow  shadow with a meniscus-
shaped upper surface . There is also widening of the pleura that  lines the posterior
thoracic wall .
If  the posterior part of one or both diaphragms is obscured or the posterior costophrenic
angle is obliterated, this indicates the presence of pleural fluid.  Then we should be do
further diagnostic tests .  Moreover, the presence of clinically significant amounts of free
pleural fluid can be nearly excluded , if both posterior costophrenic angles are clear and
sharp. In the postero - anterior chest radiograph , lateral costophrenic angle is blunted
with  increasing amounts of fluid . The entire outline of the diaphragm is lost on the
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affected side, as more fluid accumulates . The fluid then extends upwards around the
posterior , anterior and lateral thoracic walls. At the lung base, this fluid produces
opacification which is the typical meniscus shape.
Supine Position
There are three characteristics that serve to differentiate the increased density due to
parenchymal infiltrate from that due to a pleural fluid.
First, in a properly exposed film , the vascular structures of the lung will be readily
visible through the density, if the density is caused by pleural fluid.
However, vascular structures are obliterated by the silhouette effect, if  a similar density
is produced by any intrapulmonary process. Secondly ,  the density is usually completely
homogenous, if it is due to pleural fluid. Whereas, the infiltrates are usually less
homogenous, if it is caused by an intrapulmonary processes.
Third, the presence of air bronchograms . They are are present only if the increased
density is due to a parenchymal infiltrate and not due to a pleural fluid.
Ultrasound
In a patient with pleural effusion , the ultrasound can be used for the following purposes.
They are
(a) to determine the presence of pleural fluid;
(b) to identify an appropriate location for the attempted thoracentesis, chest
tube placement, or pleural biopsy;
(c) to identify loculated pleural effusion;
(d) to distinguish pleural thickening from  pleural fluid;
(e) tosemiquantify the amount of pleural fluid;
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(f) to differentiate a lung abscess from a pyopneumothorax;
(g) to assess a whether a pleurodesis is present; and
(h) to evaluate the trauma patient for the presence of a  pneumothorax or a
hemothorax.
FIGURE 1
ULTRASOUND OF LEFT LUNG AND SURROUNDING STRUCTURES
FIGURE 2.
ULTRASOUND OF RIGHT LUNG AND SURROUNDING STRUCTURES
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FIGURE 3
CHEST X RAY – POSTERIOR ANTERIOR VIEW SHOWING RIGHT SIDED
PLEURAL EFFUSION .
FIGURE 4
DIAGNOSTIC OR THERAPEUTIC THORACENTESIS
- RECOMMENDED POSITION OF THE PATIENT
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FIGURE 5
CT CHEST PLAIN SHOWING PLEURAL EFFUSION
TRANSUDATIVE PLEURAL EFFUSIONS
“Alternation in the systemic factors influencing the formation and absorption of the
pleural fluids leads to accumulation of the pleural fluid and formation of transudative
pleural effusions” .
The major causes are :
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1.Congestive Heart Failure :
“The most common cause of pleural effusion is probably the congestive heart failure
(CHF).The researchers interested in pleural effusions usually do not see most patients
with pleural effusions of  this  cardiac origin and this is the reason for the low incidence
of pleural effusions secondary to heart failure in most of the studies  . The incidence of
pleural effusions in patients with CHF is high”.
Pathophysiology :
“In the  concepts of pleural fluid formation and reabsorption in patients with heart failure
, there are significant modifications in the  recent years. It was believed in the past that
the accumulation of  the pleural fluid in patients with CHF was due to increased pressure
in the parietal or the visceral pleural capillaries. According to Starling's equation, these
increased pressures  results in a decreased removal of fluid through the visceral pleura
and an increased entry of fluid into the pleural space from the parietal pleura” .
“In patients with CHF , according to  current theories on pleural fluid formation and
reabsorption, there is a  different entry pathway and a different exit pathway for pleural
fluid.  It is believed that almost all fluid exits the pleural space through the lymphatics in
the parietal pleura rather than by passively diffusing across the visceral pleura. In patients
with CHF, accumulation of pleural fluid occurs when the rate of entry of fluid into the
pleural space exceeds the capability of the lymphatics in the parietal pleura to remove the
fluid” .
Clinical Manifestations :
“In patients with pleural effusions due to CHF they are usually associated with other
manifestations of that disease. The patient has a history of increasing dyspnea on
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exertion,  orthopnea or paroxysmal nocturnal dyspnea , increasing peripheral edema. The
dyspnea is frequently out of proportion to the size of the effusion”.
Physical examination :
“Physical examination usually reveals signs of the pleural effusions as well as signs of
both left-sided heart failure with an S3 ventricular gallop and rales and right-sided heart
failure with peripheral edema and distended neck veins”.
Investigations :
“The chest radiograph almost always reveals usually bilateral pleural effusions and
cardiomegaly. The most common cause of bilateral pleural effusions is congestive heart
failure . But only 88% of the patients studied had bilateral pleural effusions
,ifcardiomegaly is not present.  The mean volume of pleural fluid in the right pleural
space (1,084 mL) when compared to the mean volume of pleural fluid in the left pleural
space  (913 mL),was only slightly greater. Also mediastinal lymphadenopathy is common
in patients with pleural effusions that are secondary to CHF”.
Diagnosis :
If the patient has  bilateral pleural effusions and cardiomegaly,  not febrile, and no history
of pleuritic chest pain, we have to first initiate treatment of the CHF. Then we have to
observe the patient and determine whether the pleural fluid is reabsorbed. We then
perform a diagnostic thoracentesis , if the effusions do not disappear within a few day.
“One problem with this approach is that the characteristics of the pleural fluid may
change from those of a transudate to those of an exudates , since the patients are with
dieresis”.
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Serum pleural fluid albumin or protein gradient :
The serum to pleural fluid protein gradient should be examined , if the pleural fluid meets
exudative criteria but the effusion is thought to be due to CHF. If this gradient is greater
than 3.1 g/dL, additional diagnostic studies are not indicated because the pleural effusion
is probably due to the CHF .
Currently, as the protein gradient is already available when Light's criteria are measured ,
the protein gradient of 3.1 g/dL is preferred to the albumin gradient.
Pro-brain natriuretic peptide :
The measurement of the serum or pleural fluid pro-brain natriuretic peptide (pro-BNP) ,
is an another test that should be considered for establishing the diagnosis of CHF. The
level NT pro-brain natriuretic peptide (NT pro-BNP) considereddiagnostic of CHF is
1500pg/mL
Treatment
In a patient with pleural effusion secondary to heart failure the preferred treatment is to
treat the heart failure with the following drugs.,
- digitalis,
- diuretics – to reduce preload , and
- dilators - to reduce afterload .
The pleural effusion disappears , if we manage heart failure successfully. In most patients
with heart failure , the pleural effusion is effectively managed only with above
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management . Occasionally, the patients tends to be very dyspneic, if they are associated
with large pleural effusions. Such persons may get rapid relief from the dyspnea , if about
0.5L to 1.0L of pleural fluid are removed . Sometimes therapeutic thoracentesis is
indicated in patients with heart failure and large pleural effusions that are refractory to
treatment, to get symptomatic relief . So consider interventions to control the pleural
effusions , in such patients.
2. Hepatic Hydrothorax
One of the complication of hepatic cirrhosis is pleural effusion. But only when ascitic
fluid is present, pleural effusions usually occur. They are usually called as hepatic
hydrothorax.
Pathophysiology
It is evident from the foregoing studies, that the orgin of pleural fluid in these patients is
from the ascitic fluid.
“The fluid in the peritoneal cavity passes directly through the defects in the diaphragm to
the pleural space . The diaphragm may be stretched in  patients with tense ascites, causing
microscopic defects. This is because of the increased intraabdominal pressure.  There is
always a one-way transfer of fluid from the peritoneal to the pleural cavity ,in patients
with ascites. The is because of increased hydrostatic pressure in the asciticfluid” .
In some patients, the lymphatic vessels play an important role in the production of the
pleural effusion. The mechanism behind this is the transfer of ascitic fluid across the
diaphragm by the lymphatic vessels .
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To conclude , the dominant mechanism of hepatic hydrothorax is the direct movement of
fluid across the diaphragm. Because the placement of the chest tube results in diminution
in the amount of ascites, within minutes.
Clinical Manifestations
“The clinical pictures of  cirrhosis and ascites dominate in patients with pleural effusions
secondary to cirrhosis. At times, in association with large pleural effusions , these
patients develop acute dyspnea. Although the pleural effusions may be small to moderate
in size, they are frequently large and occupy the entire hemithorax. The diaphragmatic
defect permits fluid to flow into the pleural cavity  from the peritoneal cavity , until the
pleural pressure approaches the peritoneal pressure and this results in development of
large pleural effusion”.
Diagnosis
“It is usually easy to diagnose the pleural effusion that is secondary to cirrhosis with
ascites. We should  perform both a paracentesis and a thoracentesis. This is to confirm
that the ascites and pleural fluid are  compatible with the diagnosis. Also to ascertain that
they are not have high polymorphonuclear cell counts”.
The pleural fluid is occasionally blood tinged or is frankly bloody. But  due to the poor
coagulation status of the patient , such findings have no significance. The differential cell
count is dominated by  polymorphonuclear leukocytes, small lymphocytes, or other
mononuclear cells.
To rule out pancreatic ascites amylase levels should be determined. Also a cytologic
examination should be performed to rule out malignant disease. This should be done in
both pleural fluid and ascitic fluid.
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Treatment
“Since  the hydrothorax is an extension of the peritoneal fluid in patients with cirrhosis
and ascites , the management of pleural effusions always should be directed toward
treatment of the ascites” .
“The patient should be put on a low-salt diet, and moderate fluid restriction. Then
diuretics should be administered. The combination of furosemide and spironolactone , is
the best diuretic therapy. The initial starting dose is 40 mg of furosemide and 100 mg of
spironolactone and they can be titrated upto a maximum dose of 160 mg of furosemide
and 400 mg of spironolactone. This combination appears to have the optimal ratio for the
two diuretics”
3. Nephrotic Syndrome
The nephrotic syndrome is common in patients with the pleural effusion.
Mechanism of pleural fluid accumulation :
“The combination of increased hydrostatic pressure and decreased plasma oncotic
pressure , is the mechanism responsible for the transudative pleural effusion in patients
associated with the nephrotic syndrome”.
Diagnosis :
“In the typical clinical situation to diagnose pleural effusion secondary to the nephrotic
syndrome it is not difficult. But  to confirm that the pleural fluid is indeed a transudate ,a
diagnostic thoracentesis should be performed”
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“In patients with the pleural effusion and nephrotic syndrome, the possibility of
pulmonary embolism should always be considered. In all patients with the pleural
effusion and nephroticsyndrome , one should always obtain a lung scan or a CT
angiogram. It is important that evidence of deep venous thrombosis should be sought
with venograms, pulmonary arteriogram or a impedance plethysmograms, if the lung scan
or spiral CT scan is equivocal.”
Treatment :
The main aim of  treatment is  to decrease the protein loss in the urine of patients with
pleural effusion and associated with the nephrotic syndrome. This is done  to decrease the
increased extracellular volume and to increase the plasma protein.
This is best accomplished by administering
- diuretics in conjunction with a low-sodium diet,
- angiotensin-converting enzyme inhibitors.
As serial therapeutic thoracentesesonly  deplete the protein stores, theyshould not be
performed ..
EXUDATIVE PLEURAL EFFUSION
MOST COMMON CAUSES ARE :
1. Parapneumonic pleural effusion
2. Pleural effusion related  to metastatic malignancies
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3. Tuberculous pleural effusion
1.METASTAIC MALIGNANCIES AND PLEURAL EFFUSION :
“The exudative pleural effusion secondary to malignant disease involving the pleura is
the second leading cause of  exudative pleural effusion. Parapneumonic effusion ranks
first in this category”.
“Common carcinomas associated with malignant pleural effusions are :
1. Lung carcinoma ,
2.  Breast carcinoma ,
3.  Lymphoma ,
4.  Ovarian carcinoma ,
5.  Sarcoma”
Rarely carcinoma of uterus , cervix , stomach , colon , pancreas , bladder
2.TUBERCULOUS PLEURAL EFFUSION
The development of pleural effusion in a patient with absence of radiologically apparent
TB  indicates that it would be a sequelae to the primary infection that occurred    6 to 12
weeks before  or it may be due to reactivation of  TB .
Pathogenesis  of tuberculous pleural effusion :
In tuberculous patients there are subpleuralcaseous focus. Tuberculous pleural effusion
occurs due to  rupture of the sub pleuralcaseous focus in the lung to the pleural space.
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In the development of tuberculous pleural effusion the delayed hypersensitivity plays a
major role .There is clonal expansion of  lymphocytes sensitised  to the
tuberculousprotein . Initially the macrophages predominate in the pleural fluid from day 2
to day 6 and then the lymphocytes predominate in the pleural fluid.
It is clear that the delayed hypersensitivity increases the pleural capillaries permeability
to protein. There is higher rate of pleural fluid formation due to the increased levels  of
pleural fluid protein. Also there is increased levels of VEGF, which also increases the
permeability. This leads to the accumulation of pleural fluid and development of pleural
effusion .
Also there is decrease in the clearance of proteins in the pleural space. This is because of
the impedence to the clearance of proteins by the lymphatics as a result of delayed
hypersensitivity reactions .
Clinical manifestation :
“Patients with pleural TB have symptoms such as fever, dry cough ,pleuritic chest pain,
and dyspnea.  Physical findings are those of pleural effusion such as dullness to
percussion and absence of breath sounds”.
In HIV individuals there will be longer duration of illness. The incidence of chest pain is
low, but night sweats , fatigue , diarrhoea , hepatomegaly , lymphadenopathy ,
splenomegaly  are more common.
They have associated parenchymal lesions , smear for acid fast bacilli positive and also
culture positive for AFB.
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DIAGNOSIS :
“Tuberculin skin testing : Tuberculin skin testing  is almost always positive if performed
after 8 weeks of development of symptoms . So a negative skin testing after 8 weeks of
development of symptoms can be used to rule out TB. However in malnourished
individuals or HIV patients the test remains negative” .
Pleural fluid analysis :
1. Pleural fluid protein elevated and usually above 5 g/dL
2. WBC count has more than 50% small lymphocytes . If there is eosinophils it suggests
previous thoracentesis or associated pneumothorax .
3. Mesothelial cells not more than 5 % .
4. Adenosine deaminase levels more than 70 U/L
5. Interferon gamma levels more than 3.7IU/ml
6. Low pleural fluid pH and CRP levels more than 30 mg/dl
7. Pleual biopsy – demonstration of  parietal pleura granuloma , AFB , caseous necrosis.
8. Pleual fluid AFB staining and culture for mycobacteria
3.Parapneumonic effusion :
“When any pleural effusion is associated with bacterial pneumonia , lung abscess or
bronchiectasis , it is called as parapneumonic effusion” .
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An empyema is defined as pus in the pleural space. Many complicated parapneumonic
effusions are empyema.
According to Weese et al. empyema is charecterised by specific gravity greater than
1.018 , protein more than 2.5 g/dL , WBC count  more than 500 cells/ mm3 But
according to Vianna empyema is defined as pleural fluid protein more than 3.0 g/dL ,
WBC greater than 15000 / mm3 or positive bacterial cultures.
Pathogenesis :
1.Exudative stage :
“This stage is characterised by rapid accumulation  of sterile pleural fluid in pleural
space. The fluid orginates from the interstitial spaces of lung and also from the visceral
pleural capillaries due to increased capillary permeability. There is low WBC count , low
LDH level and a normal glucose level in the pleural fluid at this stage. This stage resolves
if  appropriate antibiotics is instituted”.
2.Fibropurulent stage
The pleural space is invaded by the bacteria , if antibiotics are not intiated.  In this stage
there is accumulation of large amounts of pleural fluids which is rich in
bacteria,polymorphonuclearleucocytes  and cellular debris . The visceral and parietal
pleura are covered by a continuos sheet of fibrin. This leads to the formation of loculation
and prevents the spread of pus . But this makes the insertion of chest tube difficult. In this
stage there is higher pleural fluid LDH and lower pleural fluid glucose and pH
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3.Organisation stage
This stage is characterised by pleural peel. The fibroblasts grow in to the exudates and an
inelastic membrane is produced . The lung is encased by this inelastic pleural peel and
makes it functionless. The exudates is thick at this stage and it may spontaneously drain
through the chest wall called as empyema necessitatis or into the lung producing a
bronchopleuralfistula .
The most common organisms are Staphylococcal aureus , Escherichia coli  and anaerobe
Bacteroids .
Clinical features :
Fever , cough with expectoration , chest pain are the major symptoms . In
immunocomprimised person fever may be absent . If the fever is present for more than 48
hours after the institution of antibiotics then it is called as parapneumonic effusion. The
history of alcoholism , seizures or an episode of unconsciousness should be sought as it
leads to aspiration.
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DETAILED STUDY PROPOSAL
TITLE:
A study on exudative etiology of pleural effusion in chronickidney disease in a
tertiary care hospital
AIMS AND OBJECTIVES:
“The present study is conducted:
1. To determine the demographic characteristics of patients with chronic kidney disease
developing pleural effusion.
2. To determine the incidence of exudative and transudativeetiologies of pleural effusion
in CKD patients.
2. To find the incidence of various exudative etiologies of pleural effusion in CKD
patients”.
MATERIALS AND METHODS:
STUDY POPULATION:
“This study is a hospital based Prospective study conducted between February2016 to
July 2016, among Patients with Chronic Kidney disease and pleural effusion admitted in
medical ward in OfGovernment RajajiHospital, Madurai”.
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INCLUSION CRITERIA:
1. Patients with pleural effusion and an estimated Glomerular filtration rate (GFR)
<60ml/min/1.73m2 for 3 or more months, with or without kidney damage.
GFR was calculated using MDRD formula
2. Age >13 yrs.
Exclusion criteria:
1. Age <13 yrs.
2. Patients with HIV.
3. Patients with bleeding disorders.
4. Severe co morbidities like recent MI.
5. Patients not willing for thoracocentesis.
Study Procedure: A clinically suspected case of pleural effusion in a chronic kidney
disease patient is diagnosed by Chest X-ray and ultrasound chest. Detailed demographic
and clinical parameters including age, sex, smoking history, clinical symptoms with
duration (Cough, fever, sputum production, haemoptysis, chest pain, breathlessness) and
clinical signs (Pallor, clubbing, enlarged neck nodes, pulse rate, blood pressure) and
systemic examination will be evaluated in all patients. In addition to chronic kidney
disease, history for other co-morbid illness and habits like smoking and alcoholism will
betaken.Co-morbid illnesses were defined as the presence of coexisting cardiac failure,
ischemic heart disease, chronic lung disease (COPD), chronic liver disease, malignancies,
neurological diseases and diabetes mellitus.
All patients will be subjected to blood investigations including Complete blood
count, ESR, Blood sugar, renal function tests and Liver function tests and urine routine
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examination. Sputum if present, for ZN stain, Gram’s stain, culture and sensitivity.
Chest radiograph is classified according to the size of effusion. The size of the
effusion will be assessed on the posterior-anterior radiograph by visually estimating the
area of the hemi-thorax occupied by pleural fluid. Pleural effusions were deemed to be
minimal if it occupied less than one third of hemi-thorax, moderate if it occupied between
one third to two third, and massive if it occupied more than two thirds of the hemi-thorax.
Thoracocentesis will be  performed using a 20 gauze needle syringe and the fluid is
studied forthe gross appearance, total WBC count, differential count, RBC count, protein,
glucose, ADA, LDH, cytology and culture. Pleural fluid is classified as exudative
effusion or transudative effusion by applying LIGHTŚ Criteria.
“Exudative Pleural Effusions meet at Least one of the following Criteria, whereas
Transudative
Pleural Effusions meet none (Light's Criteria):
Pleural fluid protein divided by serum protein greater than 0.5
Pleural fluid LDH divided by serum LDH greater than 0.6
Pleural fluid LDH greater than two thirds of the upper normal limit of serum LDH”.
According to the above criteria patients with exudative pleural effusion are
identified. The common exudative causes of pleural effusion are tuberculosis, bacterial
infections, bronchogenic carcinoma, lymphomas, pulmonary infarction, collagen vascular
diseases and Meig’s syndrome. To identify each of these conditions clinical examination
followed by appropriate investigations will be made.
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Serial
no.
Causes Investigations
1 Tuberculosis CXR, sputum examination, pleural
fluid analysis, LDH,  ADA levels in
pleural fluid, gene expert
2. Bacterial infections –Staph aureus,
Streptococuus, E-coli, enterococcus,
klebsiella, H.Inflenza, pseudomonas
Pleural fluid gram stain, pleural fluid
analysis, pleural fluid culture.
3 Bronchogenic carcinoma CXR, Pleural fluid analysis
4 Lymphomas CXR, USG, complete blood count
with peripheral smear.
5. Pulmonary infarction CXR, ECG, ECHO
6. Collagen vascular diseases CBC with peripheral smear, ANA
7. Meig’s syndrome CXR, USG
LABORATORY INVESTIGATIONS
Complete hemogram
Renal function test
Liver function test
Electrocardiogram
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Echocardiogram
Sputum AFB, gram stain & culture
Chest x-ray PA view
Pleural fluid analysis
ADA, LDH, ANA, NAAT
DESIGN OF STUDY:
Hospital based prospective observational study.
PERIOD OF STUDY:
February to July 2016 (6 months)
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RESULTS AND INTERPRETATION
Age Distribution: Out of the 40 patients included in the study, patients less than 20 years
of age were 1(2.85%), between 21 to 40 years of age were 6(14.28%) and 41 to 60 years
of age were 16(40%) and above 60 years were 17(42.85%).
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Sex Distribution: The study consisted of 40 patients, out of which 34(85%) were males
and 6(15%) were females. Sex ratio (Male: Female) is 5.6:1
MALES
85%
FEMALES
15%
SEX DISTRIBUTION
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Smoking Status: Of the 40 patients,23(58%) were  smokers, 17(42%) were non
smokers,among the non smokers 6 were females and 10 males …..
Comorbidities and Associated Diseases: In the present study 16(40%) had diabetes and
26(65%) were hypertensive, 12(29%) had both diabetes and hypertension, 12(30%) had
history of coronary artery disease and 12(31%) had history of tuberculosis and 12(31%)
had other comorbidities like sle,malignancy etc.
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Etiology of Pleural
Effusion: Etiology
No. of Cases (n=35)
Cardiac failure 13(31 %)
Tuberculosis 12(28 %)
Malignancy 4(9 %)
Connective tissue disorders 1(2 %)
Parapneumonic effusion 4(11.4 %)
Uremic effusion 6(14.2 %)
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Type of Effusion: In 13 cases it was transudative effusions and in 27 cases it was
exudative effusions..among the exudative effusion 24 were males and 3 females ,
66
Chest X-Ray Findings: Bilateral effusion were observed in 17 cases, and unilateral
effusion were observed 23,among that 21 males and 2 females.
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No. of Pleural Effusion Cases in Relation to Severity of CKD: Of the 40 cases, no
cases were seen in stage 1 and 2, 3,13 (32.5%) cases were seen in stage 4, 17(42.5%)
cases were seen in stage 5 …..
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Lab Investigation Results: The mean haemoglobin (HB%) value was , 8.1±1.3, .The
mean random blood sugar level was 153.8±85, and the mean blood urea level was 120±
55.The mean serum creatinine was 4.0±2.75.
Lab data values
haemoglobin 8.1±1.3
The mean random blood sugar level 153.8±85
The mean blood urea 120± 55.
mean serum creatinine 4.0±2.75
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DISCUSSION:
“Chronic kidney disease (CKD) is becoming a major global health problem. It is
estimated that 1, 00, 000 new patients of end stage renal disease (ESRD) enter renal
replacement programs annually in India.Given the prevalence of CKD, the frequency
(>50%) of haemodialysis in these patients, and the propensity for these patients to have
pleural disease, it is not surprising that the constellation of CKD, haemodialysis, and
pleural effusion is common”.
“So the aim of the present study was to look at the various etiologies of pleural effusion
occurring in chronic kidney disease patients, and their characteristics. After getting
informed consent 40 patients were included in the study of which 34 were males and 6
were females. Mean age of the group was 52.88yrs. Patients above 40 years constituted
82.5%”.
Comorbidities:
In the present study of the 40 patients, all of them complained of dyspnoea (100%),
11(27.4%) had chest pain, 15(42.8%) had cough, and 12(30%) complained of fever, 10
(25%) had significant loss of appetite and loss of weight, 19 cases (47.28%) had pedal
oedema. The dyspnoea in many patients may also be due to other co morbidities like
anaemia and cardiac dysfunction. When the dyspnoea is accompanied by a pleuritic chest
pain or fever or cough, it may imply an under lying pleuropulmonary pathology.
Hypertension was the common comorbidity26 (65%) followed by diabetes mellitus
16(40%).
Radiology of Pleural Effusion:
In the present study bilateral pleural effusion was present in 17 cases (42.8%) and
unilateral pleural effusion in 23 cases.
In pleural effusion due to heart failure 13 out of 13[33%] cases were bilateral, in
tuberculous effusion mostly unilateral.
Type of Effusion:
In the present study transudative pleural effusions were 13(33%), all were bilateral, and
exudative pleural effusions were 27(67%), out of which 4 were bilateral, 23 were
unilateral.
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Etiology of Pleural Effusion:
In the present study the aetiology of pleural effusion was attributed
to cardiac effusion in 13(31%) cases out of 40 cases, tuberculous pleural effusion in
12(28 %) cases, uremic pleural effusion in 6(14.2 %) cases, and in 4(11.4 %) cases
parapneumonic effusion was present. Malignant pleural effusion was present in 4(9 %)
cases, pleural effusion due to connective disorder was present in 1(2 %) cases.
Pleural Effusion Characteristics in Individual Conditions:
Tuberculous Pleural Effusion:
Chronic kidney disease patients are at a growing risk for
tuberculosis (TB) worldwide. A high incidence of TB has been reported among patients
with CKD in India, 8.7% in patients on maintenance dialysis and 12.3% in renal allograft
recipients.therapy predispose CKD patients to active TB Defective-cell-mediated immune
response and uraemia, along with co morbid conditions such as diabetes and prolonged
corticosteroid and immunosuppressive
In addition to this, impairment of CMI makes infection with
mycobacterium tuberculosis more difficult to detect and more likely to progress to TB
disease than in immune competent individuals. Smear negative and extra-pulmonary
forms are more frequent than in an immunocompetent individual. A high incidence of
post-transplant TB has been reported in India, especially miliary TB.
In the present study 28% of pleural effusions were due to
tuberculosis. . Total number of male patients were 8, female patients were 2. Male to
female ratio was 4:1. Fever was present in 70% of the patients, cough was present in 70%
of the patients, dyspnoea was present in all patients.
Chest pain was complained by 50% of the patients,loss of appetite
and loss of weight,pedaledema were observed. Radiologically all are unilateral effusions.
40% of patients had given past history of tuberculosis. some of patients were onhaemo
dialysis. Thus from the above data it is suggested that all patients who are known to have
advanced CKD, and those who are on dialysis, and those with a transplantation, should be
screened actively for tuberculosis. In patients with exudative effusions, despite failure to
establish tuberculosis aetiology, if therapy with common antibiotics fails, a trial of anti-
tubercular therapy is justified especially in high tuberculosis endemic country like India.
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Uremic Pleural Effusion:
Uremic patients undergoing haemodialysis may suffer from uremic
pleural effusion. Uremic pleuritis is a fibrinous pleuritis that results from unknown
putative agents.
The characteristic exudative effusion is typically serosanguineous
or hemorrhagic with increased lymphocytes. Uremic pleuritis has been reported in 1 to
57%.7,8 of patients with end-stage renal disease. The typical patient with uremic pleural
effusion has been undergoing dialysis for one or two years. Patients usually have
symptoms at the onset of effusion, with fever, cough, or chest pain. pleural effusion
generally resolves with continued dialysis over several weeks. Some may recur and some
patients will progress to fibro thorax.
In the present study, 14% of the pleural effusions were due to
uraemia. . Total number of male patients were 5, female patients were 1. Fever was
present in 60% of the patients, cough was present in 60% of the patients, and dyspnoea
was present in all patients. Chest pain was complained by 40% of the patients. Pedal
oedema was present in 80% of the patients.
Parapneumonic Effusion:
CKD and ESRD patients, per se, have a greater risk of pulmonary
infections. Among pulmonary infections, pleural empyema has a high mortality. It is
usually a complication of pneumonia but may arise from haematogenous seeding from an
extra pulmonary focus,Klebsillae pneumoniae was the most frequently isolated sole
pathogen.
“However, in ESRD patients receiving maintenance dialysis, aerobic Gram-positive
organisms were the predominant pathogens. S aureus and Enterococcus spp. were the
most frequently isolated pathogens”.
Most stage 4 CKD patients with culture-positive empyema had
underlying comorbidities, most patients were relatively Immunocompromised with either
diabetes mellitus[40%] , malignancy (9%), or liver cirrhosis.
“It is well known that immunocompromised patients are prone to pleural involvement
with fungal or aerobic GNB infections. The markedly high rate of Gram-negative
bacterial infection in the empyema of the stage 4 CKD patients may be associated with
the high incidence of underlying disease and poor renal function. However, ESRD
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patients receiving long-term dialysis had a higher rate of bacteraemia and aerobic Gram-
positive empyema despite a similar incidence of underlying disease and a similar
frequency of central venous catheter implants.
However In the present study 11% of patients had
parapneumonic effusions. Total number of male patients was 4, there were no female
patients. Dyspnoea was present in all patients, fever and cough with expectoration
present.
Radiologically all were unilateral effusions. Pleural fluid analysis showed a mean total
leukocyte  of polymorph predominance, ADA levels of 53±6.40,  pleural fluid for culture
and sensitivity showed growth of klebsiella in two cases, streptococcus pneumonia in one
case and pseudomonas in third case.
Pleural Effusions due To Heart Failure:
Congestive heart failure (CHF) is probably the most common cause
of pleural effusion in chronic kidney disease.In the past, it was believed that pleural fluid
accumulation in CHF was due to increased pressure in the capillaries in visceral or
parietal pleura which resulted in an increased entry of fluid into the pleural space from
parietal pleura and a decreased removal of fluid through visceral pleura.
Current theories propose that pleural fluid accumulates in patients with
CHF when they have left ventricular failure. The high pressures in pulmonary capillaries
lead to increased amounts of fluid in the interstitial spaces. Which enters the pleural space
through the highly permeable visceral pleura. Fluid accumulates when the entry of fluid
into the pleural space overwhelms the capacity of the lymphatics in the parietal pleura to
remove the fluid. Small amounts of fluid may enter the pleural space from the capillaries
in either pleural surface. Elevation of systemic venous pressure may decrease the
lymphatic clearance from the pleural space.
Pleural effusions due to CHF produce dyspnoea on exertion
frequently out of proportion to the size of the effusion, peripheral oedema, orthopnoea or
paroxysmal nocturnal dyspnoea. Signs of both right-sided heart failure, left-sided heart
failure and pleural effusions may be seen. Chest radiograph almost always reveals
cardiomegaly and usually bilateral pleural effusions. CHF is by far the most common
cause of bilateral pleural effusion. If patient is febrile, has pleural effusions that are
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greatly disparate in size, has unilateral pleural effusion, pleuritic chest pain, or does not
have cardiomegaly, an alternative diagnosis must be sought.
A test useful for establishing diagnosis of CHF is measurement of
serum or pleural fluid pro-brain natriuretic peptide (pro-BNP). When the ventricles are
subjected to increased pressure or volume, BNP is released. Levels below 100pg/mL
make CHF unlikely, whereas above 500pg/mL are considered diagnostic of CHF.
In the present study13[ 31%] of pleural effusions were present due
to heart failure. None of the patients had fever,anddyspnea,cough,pedaledema are
predominant symptoms.
Radiologically all were bilateral effusions. most of patients had cardiomegaly in chest x
ray.
Malignant Pleural Effusion:
In the present study 4(9%) cases were due to malignancy; among
that 3 were lung carcinoma and 1  breastcarcinoma,the pleural fluid shows hemorrhagic
effusion and also recurrent effusion…so if patient have recurrent hemorrhagic effusion,
search malignant causes.
Connective Tissue Dissorders:
In 1(2%) of the 40 cases the effusion was due to systemic lupus
erythematosis. The above findings suggest that though heart failure is the single most
common cause of pleural effusion in CKD patients other causes like tuberculosis,
uraemic effusions, parapneumonic effusions must be considered and investigated in the
appropriate setting.
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CONCLUSION:
There is a high prevalence of exudative pleural effusions in our study. So, all
patients with chronic kidney disease and pleural effusion, thorough search
for exudative causes must be done.
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SUMMARY
 Pleural involvement is common in patients with chronic renal
insufficiency mainly stage 4 and 5.
 Heart failure and TB was the most common cause among these
effusions.
 Other causes included Para pneumonic effusions, malignancy and
uraemia.
 The presence of unilateral effusion and absence of Cardiomegaly on
chest x-ray, suggests a diagnosis other than heart failure, such as
tuberculosis, uraemia and parapneumonic effusions which deserve
prompt thoracocentesis, as these cannot be differentiated clinically.
 Tuberculous effusion must be differentiated from uremic effusion,
since management is different.
 Previously transudative effusions were thought to be  more common
in CKD, but our study result shows that the  incidence of  exudative
effusion is more common than transudative effusions  due to high
incidence of tuberculosis,
 Thereby, all the CKD patients having unilateral pleural effusion ,
exudative etiologies should be ruled out.
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PROFORMA:
Name:
Age / Sex:
IP no:
Occupation:
Presenting complaints:
Past History:
H/o DM, HT, CVD,CAD,DRUG INTAKE, Thyroid disorders,
malignancies pulmonary or extra pulmonary tuberculosis , CLD, COPD.
Personal history
smoker/ nonsmoker
alcoholic/ non alcoholic
Family H/o CKD
Clinical Examination:
General Examination
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy, hydration
status
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Vitals:
PR
BP
RR
SpO2
Systemic examination:
CVS:
RS:
ABDOMEN:
CNS:
Laboratory investigations:
Complete hemogram
Renal function test
Liver function test
Sputum AFB, gram stain & culture
Chest x-ray PA view
Pleural fluid analysis
Urine routine
Diagnosis
84
NAM
E
AGE/
SEX
sex
SMO
KER
SHT
DM
CAD
TB
OTHE
RS
CXR/
PE
PLEU
RAL F
LUID
,T/EH
B
UREA
CR
STAG
ES
ADA
ECHO
/EF
CAUS
ES
subra
mani
45/m
male
y
Y
 +
 +
 +
U
EXUD
ATE
8.2
160
6.4
5     +
65TB
peru
mal
69/m
male
y
Y
 +
 +
  -
U
EXUD
ATE
8.1
173
6.67
5 -
65PN
E
sarav
anan
25/m
male
y
N
 -
 -
  -
U
EXUD
ATE
6.7
160
6.5
5 -
65U
REMI
A
karup
pia
63/m
male
n
N
 -
 -
 +
U
EXUD
ATE
7.9
95
3.7
4     +
65TB
kaliy
appa
n
69/m
male
y
N
 -
 -
 +
U
EXUD
ATE
7.7
93
3.8
4     +
65TB
ibrah
im
33/m
male
n
Y
 -
 -
  -
U
EXUD
ATE
6.9
175
5.4
5 -
65U
REMI
A
mun
iyand
i
51/m
male
y
Y
 +
 -
  -
U
EXUD
ATE
7.8
170
6.7
5 -
65U
REMI
A
dura
imur
ugan
64/m
male
n
Y
 -
 -
 +
U
EXUD
ATE
6.6
140
5.9
5     +
65TB
allav
udee
n
  67/m
male
y
Y
 +
 +
 +
U
EXUD
ATE
8
160
5.8
5     +
65TB
sasik
mar
53/m
male
n
N
 -
 -
 +
U
EXUD
ATE
6.9
168
6.6
5     +
65TB
velus
amy
44/m
male
y
Y
 -
 -
 +
U
EXUD
ATE
8.5
102
4
4     +
65TB
pand
ian
37m
ale
n
N
 -
 -
  -
U
EXUD
ATE
8
137
4.3
4 -
65PN
E
kand
han
65m
ale
y
Y
 +
 +
  -
U
EXUD
ATE
7
172
6.6
5 -
65U
REMI
A
kesa
van
49m
ale
n
N
 -
 -
 +
U
EXUD
ATE
9
90
4
4 +
65TB
laksh
mi
19fe
male
n
N
 -
 -
  -
SLE
U
EXUD
ATE
7.5
120
3.7
4 -
65SL
E
sang
ili
58m
ale
y
Y
 +
 +
  -
U
EXUD
ATE
7.9
112
9.3
4 -
65U
REMI
A
laksn
mana
n
39m
ale
n
N
 -
 -
  -
U
EXUD
ATE
7.1
170
6.6
5 -
65U
REMI
A
subb
amm
al
67m
ale
n
N
 +
 +
  -
CA B
REAS
TB
EXUD
ATE
6.6
169
6.5
5 -
65CA
 BREA
ST
joyth
i
51fe
male
n
Y
 -
 -
 +
U
EXUD
ATE
7
105
3.9
5     +
65TB
MA
STE
R C
HA
RT
85
mani
vann
a
64m
ale
n
N
 -
 -
 +
U
EXUD
ATE
7.6
127
6.2
5     +
65TB
karup
pasa
my
63m
ale
y
Y
 +
 +
 +
B
EXUD
ATE
8
133
6.1
5     +
65TB
ravi
65m
ale
y
N
 -
 -
  -
CALU
NG
U
EXUD
ATE
8
146
6.5
5 -
65CA
LUNG
selva
guru
43m
ale
y
Y
 -
 -
  -
U
EXUD
ATE
8.5
151
6.1
5 -
65PN
E
vadiv
el
44m
ale
n
N
 -
 -
  -
U
EXUD
ATE
9
125
5.4
5 -
65PN
E
vallia
mma
l
61fe
male
n
N
 +
 +
 +
B
EXUD
ATE
7.9
153
6.4
5     +
65TB
rama
n
50m
ale
y
Y
 -
 -
  -
CA LU
NG
U
EXUD
ATE
7.7
156
6.5
5 -
65CA
 LUN
G
mun
iappa
n
59m
ale
y
Y
 +
 -
  -
CA LU
NG
B
EXUD
ATE
8.1
160
7
5     +
65CA
 LUN
G
parth
asara
thy
35m
ale
y
N
 -
 -
  -
B
TRAN
S
9.5
69
3
4
35CC
F
alex
39m
ale
y
Y
 -
 -
  -
B
TRAN
S
9.4
75
3.6
4
45CC
F
revat
hy
47fe
male
n
Y
 -
 -
  -
B
TRAN
S
9
94
4.2
5
39CC
F
rasu
49m
ale
y
Y
 -
 -
  -
B
TRAN
S
8.1
85
4
4
41CC
F
sakth
ivel
45m
ale
y
Y
 -
 -
  -
B
TRAN
S
9.5
89
4.8
5
43CC
F
mano
nman
i
55fe
male
n
N
 +
 -
  -
B
TRAN
S
8.7
90
5.1
5
36CC
F
jegan
nath
an
65m
ale
y
Y
 +
 +
  -
B
TRAN
S
8.2
94
5
5
38CC
F
moh
amm
ed is
mail
61m
ale
y
Y
 -
 -
  -
B
TRAN
S
8.4
95
5.2
5
35CC
F
rathn
am
62m
ale
y
Y
 -
 -
  -
B
TRAN
S
8.5
102
4.7
5
42CC
F
kalee
swar
i
64fe
male
n
Y
 -
 +
  -
B
TRAN
S
8
79
3.3
4
40CC
F
kalia
peru
mal
55m
ale
y
Y
 -
 -
  -
B
TRAN
S
7.9
83
4
4
60CK
D
rajas
ekar
61m
ale
y
Y
 +
 -
  -
B
TRAN
S
8.5
87
3.9
4
62CK
D
saha
yaraj
63m
ale
y
N
 +
 +
  -
B
TRAN
S
9.1
92
4.9
5
60CK
D
MA
STE
R C
HA
RT
86
ABBREVIATION
CKD Chronic Kidney Disease
PE Pleural Effusion
U Urea
Cr Creatinine
CXR Chest X Ray
Pl Pleural Fluid Analysis
E Exudative
T Transudative Effusion
GE Gene Expert
CAD Coronary Artery Disease
Tb Tuberculosis
DM Diabetes Mellitus
HT Hypertension
UL Unilateral
BL Bilateral
RFT Renal Function Test
RBS Random Blood Sugar
Hb Haemoglobin
CCF Congestive Cardiac Failure
PNE Para Pneumonic Effusion
SLE Systemic Lupus Erythematosis
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